Company Profile

Protext Mobility, Inc. is a biotech company developing a hemp/cannabidiol (CBD) - cannabis medicines platform for the legal cannabis industry, using live plant extraction processes and technologies. The Company engages in the research, testing and development of bioavailable botanical products all-natural ingredients formulated for nutraceutical and pharmaceutical applications using proprietary live plant extraction technology. The Company's subsidiaries include Plandai Biotechnology, Cannabis Biosciences, Inc., and RSAMMD Acquisitions LLC.

Employees

Sector

Biotechnology & Medical Research

More about the company

08/10/25	Protext Mobility, Inc. Announces J. M. K. Nkosi as Member of Advisory Board	CI
01/11/22	Protext Mobility, Inc and RSAMMDA LLC Provides the Shareholder Update	CI
29/10/21	ProText Mobility, Inc. Provides Updates on Research Conducted At A Licensed Facility	CI
19/01/19	ProText Mobility, Inc. cancelled the acquisition of 60% in Growprocess, Inc.	CI
19/01/18	ProText Mobility, Inc. signed a letter of intent to acquire 60% in Growprocess, Inc.	CI
23/05/17	ProText Mobility, Inc. has Changed its Name to Protext Pharma, Inc	CI
04/05/17	Protext Mobility, Inc. to Conduct Human Clinical Trial with Its Product Phytofare Catechin Complex	CI
27/03/17	ProText Mobility, Inc. acquired Cannabis Biosciences Inc. from Plandaí Biotechnology, Inc. for $0.12 million.	CI
07/03/17	Protext Mobility, Inc. Engages in the Development of Pharmaceutical Applications for the Highly Bioavailable Phytofare®	CI
31/12/16	Plandai SA completed the acquisition of ProText Mobility, Inc. in a reverse merger transaction.	CI
23/12/16	Plandai SA agreed to acquire ProText Mobility, Inc. in a reverse merger transaction.	CI

06-12	Protext Mobility Inc. (OTCID: TXTM) Unveils New Corporate Website and Investor Relations Platform to Support Strategic Growth and Exchange Uplisting	AQ
03-13	ProText Mobility Inc. (OTC: TXTM) Updates Shareholders on Strategic Developments, Liquidity, and Stock Purchases	AQ
01-20	Protext Mobility, Inc. (OTC: TXTM) is thrilled to share a transformative update, advancing uplisting readiness with a preliminary Deloitte engagement	AQ
11-19	Protext Mobility, Inc. (OTC: TXTM) Provides Shareholder Update	AQ
11-17	Protext Mobility, Inc. (OTC: TXTM) Announces Strategic TruLeaf Partnership & Next-Level Innovation	AQ

Manager	Title	Age	Since
Plooy Du Dylon CEO	Chief Executive Officer	-	-
Ahmed Jamaloodeen PSD	President	-	05/09/2001

Director	Title	Age	Since
Ahmed Jamaloodeen CHM	Chairman	-	05/09/2001
Plooy Du Dylon BRD	Director/Board Member	-	05/09/2001

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROTEXT MOBILITY, INC.	-6.67%	-9.68%	-	-	48.35M
ARGENX SE	+1.44%	-1.25%	+63.52%	+114.88%	55.19B
WUXI APPTEC CO., LTD.	+4.60%	+3.02%	+58.20%	+47.16%	45.75B
BIONTECH SE	-1.44%	+0.39%	-12.94%	-19.24%	22.98B
INSMED INCORPORATED	-2.69%	-2.10%	-3.68%	+379.00%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	+3.22%	-0.84%	+27.88%	-34.00%	16.26B
GENMAB A/S	+0.58%	+1.08%	+16.73%	-38.06%	15.42B
EXELIXIS, INC.	-1.01%	-2.30%	+27.42%	+171.92%	13.05B
PHARMAESSENTIA CORPORATION	+4.95%	+11.70%	+123.63%	+252.19%	12.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.07%	+0.14%	+29.37%	-	12.37B
Average	+0.60%	+2.23%	+36.68%	+109.23%	23.8B
Weighted average by Cap.	+1.63%	+1.48%	+40.92%	+99.91%

ProText Mobility, Inc. Stock Other OTC

Stocks

TXTM

US74371E2046

Biotechnology & Medical Research

Latest news : ProText Mobility, Inc.

Press Releases: ProText Mobility, Inc.

Quotes and Performance

Managers and Directors: ProText Mobility, Inc.

Bio Therapeutic Drugs

Company Profile